Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients
Recently, an increase in the incidence of severe forms of prostate cancer, in particular castration-resistant prostate cancer (CRPC) has been noticed. Treatment of CRPC patients is associated with increasing expenses and thus impacts the healthcare budgets at various levels. The aim was to study the...
Salvato in:
| Autori principali: | , |
|---|---|
| Natura: | Libro |
| Pubblicazione: |
IRBIS LLC,
2017-11-01T00:00:00Z.
|
| Soggetti: | |
| Accesso online: | Connect to this object online. |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
Lascia un commento!